Skip Navigation


Annals of Oncology Advance Access originally published online on November 9, 2006
Annals of Oncology 2007 18(2):293-298; doi:10.1093/annonc/mdl410
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Material
Right arrow All Versions of this Article:
18/2/293    most recent
mdl410v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Younis, T
Right arrow Articles by Skedgel, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Younis, T
Right arrow Articles by Skedgel, C
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

breast cancer

Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer

T Younis1,*, D Rayson1, R Dewar2 and C Skedgel1

1 Department of Medicine, Dalhousie University at Queen Elizabeth II Health Sciences Centre
2 Cancer Care Nova Scotia, Halifax, Nova Scotia, Canada

* Correspondence to: Dr T. Younis, Department of Medicine, Dalhousie University at Queen Elizabeth II Health Sciences Centre, 454 Bethune Building, 1278 Tower Road, Halifax, NS B3H 2Y9 Canada. Tel: +1 902-473-6054; Fax: +1 902-473-6186; E-mail: tallal.younis{at}cdha.nshealth.ca

Background: To determine cost-effective (CE) strategies comparing adjuvant upfront aromatase inhibitor (AI) with sequential tamoxifen (TAM) AI in postmenopausal (PM) women with breast cancer (BC).

Design: A Markov model was constructed to calculate cumulative costs and quality-adjusted life year (QALY) gains for upfront AI and TAM-AI in a hypothetical cohort of 60-year-old PM women with BC. Costs, utilities and probabilities were derived from the literature. The hazard ratios (HRs) of AI strategies were applied to a baseline cancer recurrence risk (RR) to determine CE strategies at the $50,000/QALY gain threshold. A direct payer perspective is utilized, and costs and benefits were discounted at 3%.

Results: Two-way sensitivity analyses are presented to determine CE strategies across a wide range of HRs and in different clinical scenarios including varying RRs (low, average, high and very high). TAM-AI is the preferred CE strategy at low and average RR, while upfront AI is CE at very high RR. The CE strategy in patients with high RR was dependent on the scenario examined.

Conclusions: This model may help health care providers select CE-adjuvant AI strategies in PM women with BC, until further direct evidence is available from randomized clinical trials.

Key words: adjuvant therapy, aromatase inhibition, breast cancer, costs, utility

Received for publication July 30, 2006. Revision received September 26, 2006. Accepted for publication October 5, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.